Live Breaking News & Updates on இயக்குனர் வெளிப்புறம் தகவல்தொடர்புகள்

Stay updated with breaking news from இயக்குனர் வெளிப்புறம் தகவல்தொடர்புகள். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Hovione completes its Phase 2 clinical trial of the first minocycline ophthalmic showing promise in Dry Eye Disease asso


CET
Hovione completes its Phase 2 clinical trial of the first minocycline ophthalmic showing promise in Dry Eye Disease asso
CORK, Ireland, March 17, 2021 /PRNewswire/ Hovione announced at the Ophthalmology Innovation Summit (OIS) Dry Eye Showcase the successful completion of its Phase 2 clinical trial in 270 patients with Dry Eye caused by Meibomian Gland Dysfunction (MGD). The well controlled and representative study was conducted across 26 clinical sites in the United States and tested 2 different strengths of minocycline against vehicle in a 1:1:1 randomization. This is the first dry eye therapy targeting MGD patients with ocular inflammation demonstrated by an MMP-9 based diagnostic and the first and only ophthalmic formulation of minocycline in clinical development, contingently named Meizuvo®. ....

United States , New Jersey , George Magrath , Prnewswire Hovione , Carla Vozone , Contactisabel Pina , Courtney Smith , Contract Development , Communications Tel , Business Development Licensing , Lexitas Pharma Services , Manufacturing Organization , Ophthalmology Innovation Summit , Dry Eye Showcase , Dry Eye , Meibomian Gland Dysfunction , Visual Analogue Scale , Cornea Fluorescein Staining , Vice President , Clinical Perspectives , Dry Eye Disease , Minocycline Ophthalmic , Business Development , Isabel Pina , Director External Communications , ஒன்றுபட்டது மாநிலங்களில் ,

Hovione completes its Phase 2 clinical trial of the first minocycline ophthalmic showing promise in Dry Eye Disease associated with Inflamed Meibomian Gland Dysfunction


Hovione completes its Phase 2 clinical trial of the first minocycline ophthalmic showing promise in Dry Eye Disease associated with Inflamed Meibomian Gland Dysfunction
News provided by
Share this article
Share this article
CORK, Ireland, March 17, 2021 /PRNewswire/  Hovione announced at the Ophthalmology Innovation Summit (OIS) Dry Eye Showcase the successful completion of its Phase 2 clinical trial in 270 patients with Dry Eye caused by Meibomian Gland Dysfunction (MGD). The well controlled and representative study was conducted across 26 clinical sites in the United States and tested 2 different strengths of minocycline against vehicle in a 1:1:1 randomization. This is the first dry eye therapy targeting MGD patients with ocular inflammation demonstrated by an MMP-9 based diagnostic and the first and only ophthalmic formulation of minocycline in clinical development, contingently named Meizuvo®. ....

United States , New Jersey , Isabel Pina , George Magrath , Carla Vozone , Courtney Smith , Contract Development , Business Development Licensing , Lexitas Pharma Services , Manufacturing Organization , Ophthalmology Innovation Summit , Dry Eye Showcase , Dry Eye , Meibomian Gland Dysfunction , Visual Analogue Scale , Cornea Fluorescein Staining , Vice President , Clinical Perspectives , Dry Eye Disease , Minocycline Ophthalmic , Business Development , Director External Communications , ஒன்றுபட்டது மாநிலங்களில் , புதியது ஜெர்சி , இசபெல் பினா , ஜார்ஜ் மக்ரத் ,

Hovione Launches ASD-HIPROS the Most Advanced Screening Service for Optimal Spray Dried Dispersions Formulation


Share this article
Share this article
LISBON, Portugal, Jan. 12, 2021 /PRNewswire/ Hovione, the leader in Pharmaceutical Spray Drying, today announced the launch of ASD-HIPROS, a proprietary screening service for spray dried dispersions. This platform is the most advanced and most accurate tool to identify optimal and commercially viable Amorphous Solid Dispersions formulation by Spray Drying (ASDs). During drug development, it is crucial to quickly find the optimal formulation assuring fast progress to clinical supplies and minimal formulation changes till commercialization.
ASD-HIPROS, the Hovione Intelligent PROprietary Screening methodology, is able to rapidly screen for the best combination of polymers, drug loads, surfactants and solvents by using an advanced computational tool followed by producing scale-independent representative samples of the most promising formulations, which are evaluated for performance and stability. ....

United States , New Jersey , Isabel Pina , Filipe Gaspar , Jean Luc Herbeaux , Prnewswire Hovione , Contract Development , Technology Officer , Manufacturing Organization , Pharmaceutical Spray Drying , Amorphous Solid Dispersions , Spray Drying , Hovione Intelligent , Spray Dried Dispersion , Chief Technology , Chief Operating , Director External Communications , Health Care Amp Hospitals , Medical Pharmaceuticals , Computer Software , Computer Amp Electronics , Stem Science , New Products Amp Services , ஒன்றுபட்டது மாநிலங்களில் , புதியது ஜெர்சி , இசபெல் பினா ,